Vaccine-induced effector-memory CD8+ T cell responses predict therapeutic efficacy against tumors

Journal of Immunology

Volumn 189, Issue 7, 2012, Pages 3397-3403

  Van Duikeren, Suzanne ^a   Fransen, Marieke F ^a   Redeker, Anke ^a   Wieles, Brigitte ^a   Platenburg, Gerard ^b   Krebber, Willem Jan ^b   Ossendorp, Ferry ^a   Melief, Cornelis J M ^a,b   Arens, Ramon ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ISA Therapeutics BV   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CPG OLIGODEOXYNUCLEOTIDE; CPG OLIGODEOXYNUCLEOTIDE 1826; GAMMA INTERFERON; HILTONOL; IMSAVAC L; INTERLEUKIN 7 RECEPTOR; L SELECTIN; L3 LIPOPOLYSACCHARIDE; LIPOPOLYSACCHARIDE; LPXL1 LIPOPOLYSACCHARIDE; LYMPHOCYTE RECEPTOR; MONTANIDE ISA 51; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY G1; PHOSPHATE BUFFERED SALINE; POLYINOSINIC POLYCYTIDYLIC ACID; PROTEIN E7[43-77]; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG EFFICACY; EFFECTOR CELL; FEMALE; HUMAN PAPILLOMAVIRUS TYPE 16; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; ONCOGENE; ONCOGENE E7; PRIORITY JOURNAL; T CELL DEPLETION; TUMOR REGRESSION; UTERINE CERVIX CANCER;

AMINO ACID SEQUENCE; ANIMALS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HUMAN PAPILLOMAVIRUS 16; IMMUNOLOGIC MEMORY; INJECTIONS, SUBCUTANEOUS; MICE; MICE, CONGENIC; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; PAPILLOMAVIRUS E7 PROTEINS; PREDICTIVE VALUE OF TESTS; TUMOR CELLS, CULTURED; UTERINE CERVICAL NEOPLASMS; VIRAL VACCINES;

EID: 84866551579     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1201540     Document Type: Article

References (33)

1. Turtle, C. J., and S. R. Riddell. 2011. Genetically retargeting CD8+ lymphocyte subsets for cancer immunotherapy. Curr. Opin. Immunol. 23: 299-305.
2. Iancu, E. M., P. Baumgaertner, S. Wieckowski, D. E. Speiser, and N. Rufer. 2011. Profile of a serial killer: cellular and molecular approaches to study individual cytotoxic T-cells following therapeutic vaccination. J. Biomed. Biotechnol. 2011: 452606.
3. Kaech, S. M., E. J. Wherry, and R. Ahmed. 2002. Effector and memory T-cell differentiation: implications for vaccine development. Nat. Rev. Immunol. 2: 251-262. (Pubitemid 37323225)
4. Arens, R., and S. P. Schoenberger. 2010. Plasticity in programming of effector and memory CD8 T-cell formation. Immunol. Rev. 235: 190-205.
5. Melief, C. J. 2008. Cancer immunotherapy by dendritic cells. Immunity 29: 372-383.
6. Harari, A., V. Dutoit, C. Cellerai, P. A. Bart, R. A. Du Pasquier, and G. Pantaleo. 2006. Functional signatures of protective antiviral T-cell immunity in human virus infections. Immunol. Rev. 211: 236-254. (Pubitemid 43882976)
7. Darrah, P. A., D. T. Patel, P. M. De Luca, R. W. Lindsay, D. F. Davey, B. J. Flynn, S. T. Hoff, P. Andersen, S. G. Reed, S. L. Morris, et al. 2007. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat. Med. 13: 843-850. (Pubitemid 47038186)
8. Seder, R. A., P. A. Darrah, and M. Roederer. 2008. T-cell quality in memory and protection: implications for vaccine design. Nat. Rev. Immunol. 8: 247-258. (Pubitemid 351432801)
9. Harari, A., V. Rozot, F. B. Enders, M. Perreau, J. M. Stalder, L. P. Nicod, M. Cavassini, T. Calandra, C. L. Blanchet, K. Jaton, et al. 2011. Dominant TNF-α+ Mycobacterium tuberculosis-specific CD4+ T cell responses discriminate between latent infection and active disease. Nat. Med. 17: 372-376.
10. Lin, K. Y., F. G. Guarnieri, K. F. Staveley-O'Carroll, H. I. Levitsky, J. T. August, D. M. Pardoll, and T. C. Wu. 1996. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res. 56: 21-26.
11. Arens, R., A. Loewendorf, M. J. Her, K. Schneider-Ohrum, G. R. Shellam, E. Janssen, C. F. Ware, S. P. Schoenberger, and C. A. Benedict. 2011. B7-mediated costimulation of CD4 T cells constrains cytomegalovirus persistence. J. Virol. 85: 390-396.
12. Altman, J. D., P. A. Moss, P. J. Goulder, D. H. Barouch, M. G. McHeyzer-Williams, J. I. Bell, A. J. McMichael, and M. M. Davis. 1996. Phenotypic analysis of antigen-specific T lymphocytes. Science 274: 94-96. (Pubitemid 26332731)
13. Zwaveling, S., S. C. Ferreira Mota, J. Nouta, M. Johnson, G. B. Lipford, R. Offringa, S. H. van der Burg, and C. J. Melief. 2002. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J. Immunol. 169: 350-358. (Pubitemid 34686155)
14. Fransen, F., C. J. Boog, J. P. van Putten, and P. van der Ley. 2007. Agonists of Toll-like receptors 3, 4, 7, and 9 are candidates for use as adjuvants in an outer membrane vaccine against Neisseria meningitidis serogroup B. Infect. Immun. 75: 5939-5946. (Pubitemid 350207834)
15. Kenter, G. G., M. J. Welters, A. R. Valentijn, M. J. Lowik, D. M. Berends-van der Meer, A. P. Vloon, F. Essahsah, L. M. Fathers, R. Offringa, J. W. Drijfhout, et al. 2009. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N. Engl. J. Med. 361: 1838-1847.
16. Fransen, M. F., M. Sluijter, H. Morreau, R. Arens, and C. J. Melief. 2011. Local activation of CD8 T cells and systemic tumor eradication without toxicity via slow release and local delivery of agonistic CD40 antibody. Clin. Cancer Res. 17: 2270-2280.
17. Aucouturier, J., L. Dupuis, S. Deville, S. Ascarateil, and V. Ganne. 2002. Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines. Expert Rev. Vaccines 1: 111-118. (Pubitemid 36686885)
18. Sallusto, F., J. Geginat, and A. Lanzavecchia. 2004. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu. Rev. Immunol. 22: 745-763. (Pubitemid 38680440)
19. Huster, K. M., C. Stemberger, and D. H. Busch. 2006. Protective immunity towards intracellular pathogens. Curr. Opin. Immunol. 18: 458-464. (Pubitemid 43964999)
20. Perfetto, S. P., P. K. Chattopadhyay, and M. Roederer. 2004. Seventeen-colour flow cytometry: unravelling the immune system. Nat. Rev. Immunol. 4: 648-655. (Pubitemid 39025050)
21. Voehringer, D., M. Koschella, and H. Pircher. 2002. Lack of proliferative capacity of human effector and memory T cells expressing killer cell lectinlike receptor G1 (KLRG1). Blood 100: 3698-3702. (Pubitemid 35303941)
22. Obar, J. J., and L. Lefrançois. 2010. Memory CD8+ T cell differentiation. Ann. N. Y. Acad. Sci. 1183: 251-266.
23. Dunn, G. P., H. Ikeda, A. T. Bruce, C. Koebel, R. Uppaluri, J. Bui, R. Chan, M. Diamond, J. M. White, K. C. Sheehan, and R. D. Schreiber. 2005. Interferon-gamma and cancer immunoediting. Immunol. Res. 32: 231-245.
24. Wu, C. Y., J. R. Kirman, M. J. Rotte, D. F. Davey, S. P. Perfetto, E. G. Rhee, B. L. Freidag, B. J. Hill, D. C. Douek, and R. A. Seder. 2002. Distinct lineages of T(H)1 cells have differential capacities for memory cell generation in vivo. Nat. Immunol. 3: 852-858.
25. Hansen, S. G., C. Vieville, N. Whizin, L. Coyne-Johnson, D. C. Siess, D. D. Drummond, A. W. Legasse, M. K. Axthelm, K. Oswald, C. M. Trubey, et al. 2009. Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat. Med. 15: 293-299.
26. Hansen, S. G., J. C. Ford, M. S. Lewis, A. B. Ventura, C. M. Hughes, L. Coyne-Johnson, N. Whizin, K. Oswald, R. Shoemaker, T. Swanson, et al. 2011. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 473: 523-527.
27. Wherry, E. J., V. Teichgräber, T. C. Becker, D. Masopust, S. M. Kaech, R. Antia, U. H. von Andrian, and R. Ahmed. 2003. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat. Immunol. 4: 225-234. (Pubitemid 36322131)
28. Schreiber, R. D., L. J. Old, and M. J. Smyth. 2011. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331: 1565-1570.
29. Arens, R. 2012. Rational design of vaccines: learning from immune evasion mechanisms of persistent viruses and tumors. Adv. Immunol. 114: 217-243.
30. Lake, R. A., and B. W. Robinson. 2005. Immunotherapy and chemotherapy - a practical partnership. Nat. Rev. Cancer 5: 397-405. (Pubitemid 40637831)
31. Formenti, S. C., and S. Demaria. 2009. Systemic effects of local radiotherapy. Lancet Oncol. 10: 718-726.
32. Kim, P. S., and R. Ahmed. 2010. Features of responding T cells in cancer and chronic infection. Curr. Opin. Immunol. 22: 223-230.
33. + T cells in metastases from melanoma patients. J. Clin. Invest. 121: 2350-2360.